[Management of a radiotherapy center during the COVID-19 outbreak: The experience of the Mulhouse hospital centre (France)].

The COVID-19 outbreak grows exponentially in our country. Despite most of patients develops benign symptoms, cancer patients are at risk of a severe form of the disease. Radiotherapy centres are a potential contamination place due to the number of patients treated and staff present.

Factors improving the outcome of patients re-irradiated with intensity-modulated radiotherapy (IMRT) for relapse or new head and neck cancer developed in irradiated areas.

Background: Patients with secondary/recurrent squamous cell head and neck cancer have poor prognoses. Re-irradiation is a treatment option. However, best technique to re-irradiate is not known.

[Prognostic factors for head and neck cancer reirradiation: A systematic review].

Purpose: To specify the effectiveness of head and neck cancer reirradiation and make a synthesis of prognostic factors established by published series of patients.

Materials And Methods: Original series of external reirradiation of head and neck cancer with at least ten patients were sought in Medline database.

Results: Exclusive reirradiation with or without concurrent chemotherapy offers 11 months of median overall survival, versus 6 months for chemotherapy alone, and 20 to 40% of the patients are still alive two years after treatment.

[Frameless set-up with ExacTrac system for stereotactic radiotherapy of brain metastasis: Descriptive study from five French centres].

Purpose: This study aimed to analyse the positioning protocols with the ExacTrac system, associated with a dedicated linear accelerator such as Novalis, for stereotactic treatment of brain metastases in several French centres.

Materials And Methods: A survey, including three questions about the prescription of irradiation and twenty-one questions about how the ExacTrac system is used, was sent to nine French centres owning a dedicated Novalis accelerator. Five centres have accepted to participate in the study.